Washington:
Novavax’s COVID-19 jab is more than 90 % powerful, which includes against coronavirus variants, the vaccine maker stated Monday following a substantial-scale US study.
The jab “demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall,” the enterprise stated in a statement, adding “the study enrolled 29,960 participants across 119 sites in the U.S. and Mexico to evaluate efficacy, safety and immunogenicity.”
The Maryland-headquartered enterprise stated it intended to apply for regulatory approval by the third quarter of 2021.
NEW Information RELEASE: Novavax #COVID19 Vaccine Demonstrates 90% Overall Efficacy and one hundred% Protection Against Moderate and Severe Disease in Protect against-19 Phase 3 Trial https://t.co/lIOiQXxDtDpic.twitter.com/4ePHxDpziZ
— Novavax (@Novavax) June 14, 2021
After that, it stated, it would be on course to make one hundred million doses per month by the finish of the third quarter and 150 million doses per month by the finish of the year.
“Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” stated Stanley C. Erck, Novavax’s president and chief executive.
“Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is still in great need of vaccines.”
While some wealthy nations have made progress on vaccinating their populations, there stay issues that quite a few poorer nations are getting left out of the worldwide inoculation drive.
Vaccination prices in the world’s poorest nations are far behind the Group of Seven industrialized powers and other wealthy states — in terms of doses administered so far, the imbalance among the G7 and the planet’s low-earnings nations, as defined by the World Bank, is 73 to one.
Unlike some rival jabs, Novavax’s vaccine — formally recognized as NVX-CoV2373 — does not have to be stored at ultra-low temperatures.
The enterprise stated it was “stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution.”
In theory at least, this signifies the shots ought to be more simply transported and administered in nations with much less nicely created wellness infrastructures.
()